The Duchenne muscular dystrophy market has experienced robust growth, moving from $1.07 billion in 2023 to $1.17 billion in 2024, reflecting a CAGR of 9.2%. This growth is attributed to advances in genetic research and clinical trials. The market is projected to reach $1.61 billion by 2028, with a CAGR of 8.2%. Key drivers include emerging gene therapies and regulatory support for orphan drugs.
The Duchenne muscular dystrophy market is poised for growth due to the escalating prevalence of chronic diseases. Chronic diseases, lasting for at least a year, are on the rise, and Duchenne muscular dystrophy addresses specific therapeutic needs in this context. According to the National Institutes of Health (NIH), there is a projected 99.5% increase in adults aged 50 and older with at least one chronic disease in the United States from 2020 to 2035. The broader adoption of personalized medicine to manage chronic conditions contributes to the growth of the Duchenne muscular dystrophy market, with market size expectations extending into 2023, 2024, and 2028.
Request A Free Sample Of The Global Duchenne Muscular Dystrophy Market ReportPfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Acceleron Pharma Inc., FibroGen Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., CureVac N.V., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Nihon Pharmaceutical Co. Ltd., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.
Technological advancements are driving growth in the Duchenne muscular dystrophy market. Companies are investing in research and development to maintain their market position. For instance, in April 2021, the University of Texas Southwestern’s Hamon Center for Regenerative Science and Medicine launched a new gene therapy for Duchenne muscular dystrophy (DMD) using CRISPR-Cas9 techniques. This approach aims to restore a significant portion of the dystrophin protein, which is often missing in DMD patients. The therapy successfully bypasses stop signals to restore 97% of the protein, as demonstrated through experiments with cardiomyocytes derived from DMD patients' iPS cells.
Get The Full Global Duchenne Muscular Dystrophy Market Report
The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
By Geography:The regions covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the Duchenne muscular dystrophy market in 2023.
The Duchenne Muscular Dystrophy Global Market Report 2024 furnishes information about the global duchenne muscular dystrophy market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.